Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label, single arm, multicentric, observational study to evaluate safety and effectiveness of Akynzeo®, an oral fixed dose combination of netupitant and palonosetron in the management of CINV, in the real world settings of India

Next Previous
Trial Profile

An open label, single arm, multicentric, observational study to evaluate safety and effectiveness of Akynzeo®, an oral fixed dose combination of netupitant and palonosetron in the management of CINV, in the real world settings of India

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Netupitant/palonosetron (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Glenmark Pharmaceuticals Ltd

Most Recent Events

  • 06 Jun 2023 Results of a post-hoc analysis of this observational study on NEPA, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
  • 07 Jun 2022 Status changed to completed , according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
  • 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top